Logo image of ACRV

ACRIVON THERAPEUTICS INC (ACRV) Stock Fundamental Analysis

USA - NASDAQ:ACRV - US0048901096 - Common Stock

2.38 USD
+0.14 (+6.25%)
Last: 11/17/2025, 7:30:33 PM
2.38 USD
0 (0%)
After Hours: 11/17/2025, 7:30:33 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ACRV. ACRV was compared to 533 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ACRV as it has an excellent financial health rating, but there are worries on the profitability. ACRV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ACRV had negative earnings in the past year.
In the past year ACRV has reported a negative cash flow from operations.
ACRV had negative earnings in each of the past 5 years.
ACRV had a negative operating cash flow in each of the past 5 years.
ACRV Yearly Net Income VS EBIT VS OCF VS FCFACRV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

ACRV has a Return On Assets (-54.20%) which is comparable to the rest of the industry.
The Return On Equity of ACRV (-60.09%) is better than 61.16% of its industry peers.
Industry RankSector Rank
ROA -54.2%
ROE -60.09%
ROIC N/A
ROA(3y)-33.95%
ROA(5y)-71.69%
ROE(3y)-37.89%
ROE(5y)-107.72%
ROIC(3y)N/A
ROIC(5y)N/A
ACRV Yearly ROA, ROE, ROICACRV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACRV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACRV Yearly Profit, Operating, Gross MarginsACRV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for ACRV has been increased compared to 1 year ago.
ACRV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACRV Yearly Shares OutstandingACRV Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
ACRV Yearly Total Debt VS Total AssetsACRV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

ACRV has an Altman-Z score of -0.40. This is a bad value and indicates that ACRV is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ACRV (-0.40) is better than 60.60% of its industry peers.
ACRV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.4
ROIC/WACCN/A
WACCN/A
ACRV Yearly LT Debt VS Equity VS FCFACRV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

ACRV has a Current Ratio of 10.31. This indicates that ACRV is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ACRV (10.31) is better than 81.99% of its industry peers.
ACRV has a Quick Ratio of 10.31. This indicates that ACRV is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ACRV (10.31) is better than 81.99% of its industry peers.
Industry RankSector Rank
Current Ratio 10.31
Quick Ratio 10.31
ACRV Yearly Current Assets VS Current LiabilitesACRV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.77% over the past year.
EPS 1Y (TTM)18.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ACRV is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.97% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.54%
EPS Next 2Y5.69%
EPS Next 3Y0.92%
EPS Next 5Y3.97%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACRV Yearly Revenue VS EstimatesACRV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
ACRV Yearly EPS VS EstimatesACRV Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACRV. In the last year negative earnings were reported.
Also next year ACRV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACRV Price Earnings VS Forward Price EarningsACRV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACRV Per share dataACRV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.69%
EPS Next 3Y0.92%

More info and screens

0

5. Dividend

5.1 Amount

ACRV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACRIVON THERAPEUTICS INC

NASDAQ:ACRV (11/17/2025, 7:30:33 PM)

After market: 2.38 0 (0%)

2.38

+0.14 (+6.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)N/A N/A
Inst Owners56.75%
Inst Owner Change1.17%
Ins Owners8.29%
Ins Owner Change-1.47%
Market Cap74.87M
Revenue(TTM)N/A
Net Income(TTM)-85.96M
Analysts82.67
Price Target11.39 (378.57%)
Short Float %6.55%
Short Ratio1.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.09%
Min EPS beat(2)8.02%
Max EPS beat(2)22.15%
EPS beat(4)3
Avg EPS beat(4)10.49%
Min EPS beat(4)-0.13%
Max EPS beat(4)22.15%
EPS beat(8)6
Avg EPS beat(8)8.16%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.3%
EPS NY rev (1m)0%
EPS NY rev (3m)2.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.52
P/tB 0.52
EV/EBITDA N/A
EPS(TTM)-2.25
EYN/A
EPS(NY)-2.15
Fwd EYN/A
FCF(TTM)-2.33
FCFYN/A
OCF(TTM)-2.25
OCFYN/A
SpS0
BVpS4.55
TBVpS4.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -54.2%
ROE -60.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.95%
ROA(5y)-71.69%
ROE(3y)-37.89%
ROE(5y)-107.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 197.25%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.31
Quick Ratio 10.31
Altman-Z -0.4
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)372.74%
Cap/Depr(5y)383.65%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.77%
EPS Next Y7.54%
EPS Next 2Y5.69%
EPS Next 3Y0.92%
EPS Next 5Y3.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-23.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-96.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.85%
OCF growth 3YN/A
OCF growth 5YN/A

ACRIVON THERAPEUTICS INC / ACRV FAQ

Can you provide the ChartMill fundamental rating for ACRIVON THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ACRV.


What is the valuation status for ACRV stock?

ChartMill assigns a valuation rating of 0 / 10 to ACRIVON THERAPEUTICS INC (ACRV). This can be considered as Overvalued.


Can you provide the profitability details for ACRIVON THERAPEUTICS INC?

ACRIVON THERAPEUTICS INC (ACRV) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for ACRV stock?

The Earnings per Share (EPS) of ACRIVON THERAPEUTICS INC (ACRV) is expected to grow by 7.54% in the next year.